One cornea can treat three persons' eye disease

NewsGuard 100/100 Score

A new study from India has found that one donated cornea may have the potential to treat three people with eye damage or disease.

Advances in surgical techniques now allow ophthalmologic surgeons to remove and replace only the diseased or damaged portion of the cornea.

According to the study by Rasik Vajpayee now at the University of Melbourne but formerly at the All India Institute of Medical Sciences, a cornea from a man who died of cardiac arrest was used for transplants in three patients; the corneal tissue was divided into three parts, each part was then transplanted into different patients.

Dr. Vajpayee says the procedures were performed on the same day and were all successful and such surgical techniques provide an opportunity to make use of a single donor cornea in more than one patient and will help reduce the backlog of patients with corneal blindness in countries in which there is a dearth of good-quality donor corneal tissue.

In India alone 300,000 corneas are needed each year for transplants, but only 15,000 are available.

The cornea is a clear membrane in the front of the eye; the first reported cornea transplant was performed in 1905.

The research is published in the April issue of the journal Archives of Ophthalmology.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema